Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2018 1
2020 4
2021 2
2022 3
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Metformin is a metabolic modulator and radiosensitiser in rectal cancer.
Buckley CE, O'Brien RM, Nugent TS, Donlon NE, O'Connell F, Reynolds JV, Hafeez A, O'Ríordáin DS, Hannon RA, Neary P, Kalbassi R, Mehigan BJ, McCormick PH, Dunne C, Kelly ME, Larkin JO, O'Sullivan J, Lynam-Lennon N. Buckley CE, et al. Among authors: dunne c. Front Oncol. 2023 Aug 3;13:1216911. doi: 10.3389/fonc.2023.1216911. eCollection 2023. Front Oncol. 2023. PMID: 37601689 Free PMC article.
Colonic oncostatin M expression evaluated by immunohistochemistry and infliximab therapy outcome in corticosteroid-refractory acute severe ulcerative colitis.
O'Connell J, Doherty J, Buckley A, Cormican D, Dunne C, Hartery K, Larkin J, MacCarthy F, McCormick P, McKiernan S, Mehigan B, Muldoon C, Ryan C, O'Sullivan J, Kevans D. O'Connell J, et al. Among authors: dunne c. Intest Res. 2022 Jul;20(3):381-385. doi: 10.5217/ir.2021.00073. Epub 2022 Mar 11. Intest Res. 2022. PMID: 35263959 Free PMC article. No abstract available.
Characterising the prognostic potential of HLA-DR during colorectal cancer development.
Dunne MR, Phelan JJ, Michielsen AJ, Maguire AA, Dunne C, Martin P, Noonan S, Tosetto M, Geraghty R, Fennelly D, Sheahan K, Ryan EJ, O'Sullivan J. Dunne MR, et al. Among authors: dunne c. Cancer Immunol Immunother. 2020 Aug;69(8):1577-1588. doi: 10.1007/s00262-020-02571-2. Epub 2020 Apr 18. Cancer Immunol Immunother. 2020. PMID: 32306077 Free PMC article.
Radiation-induced Bystander Effect (RIBE) alters mitochondrial metabolism using a human rectal cancer ex vivo explant model.
Heeran AB, Berrigan HP, Buckley CE, Bottu HM, Prendiville O, Buckley AM, Clarke N, Donlon NE, Nugent TS, Durand M, Dunne C, Larkin JO, Mehigan B, McCormick P, Brennan L, Lynam-Lennon N, O'Sullivan J. Heeran AB, et al. Among authors: dunne c. Transl Oncol. 2021 Jan;14(1):100882. doi: 10.1016/j.tranon.2020.100882. Epub 2020 Oct 23. Transl Oncol. 2021. PMID: 33129115 Free PMC article.
Irish data on the safety and efficacy of vedolizumab in the treatment of inflammatory bowel disease.
Judge C, McGettigan N, Ryan T, Hazel K, Singh P, Parihar V, Stack R, O'Connor A, Dunne C, Cullen G, Egan L, Harewood G, MacCarthy F, McKiernan S, Mulcahy H, Murray F, Patchett S, Sheridan J, Cheriyan D, Farrell R, Keohane J, Kelly O, McNamara D, Ryan B, O'Morain C, Sengupta S, O'Toole A, Buckley M, McCarthy J, Doherty G, Kevans D, Slattery E. Judge C, et al. Among authors: dunne c. Scand J Gastroenterol. 2020 Jul;55(7):786-794. doi: 10.1080/00365521.2020.1779340. Epub 2020 Jun 16. Scand J Gastroenterol. 2020. PMID: 32544012
Golimumab effectiveness and safety in clinical practice for moderately active ulcerative colitis.
O'Connell J, Rowan C, Stack R, Harkin G, Parihar V, Chan G, Breslin N, Cullen G, Dunne C, Egan L, Harewood G, Leyden J, MacCarthy F, MacMathuna P, Mahmud N, McKiernan S, McNamara D, Mulcahy H, Murray F, O'Connor A, O'Toole A, Patchett S, Ryan B, Sheridan J, Slattery E, Doherty G, Kevans D. O'Connell J, et al. Among authors: dunne c. Eur J Gastroenterol Hepatol. 2018 Sep;30(9):1019-1026. doi: 10.1097/MEG.0000000000001177. Eur J Gastroenterol Hepatol. 2018. PMID: 29878945
12 results